Oral micronized progesterone for prevention of preterm birth

Machine translation Machine translation
类别 Primary study
期刊International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Year 2009
連結 Pubmed, DOI

此文章收錄於 7 Systematic reviews Systematic reviews (7 references)

Loading references information
目的：评价口服微粒化孕酮（OMP）预防早产（PTB）。
方法：采用随机，双盲，安慰剂对照的150名妇女的审判至少有一个PTB每天谁收到OMP或安慰剂的100毫克两次从招聘（18-24周），直到36周或交付。
结果：PTB发生在29（39.2％），女性OMP组（n = 74），44（59.5％）相比，在对照组（n = 74，P = 0.002）。平均分娩时的胎龄是OMP组（36.1 VS34.0周，P <0.001）高。发生28和31周零6天OMP组之间少早产（RR 0.20; 95％CI，0.05-0.73，P <0.001）。新生儿年龄交付（34和32周，P <0.001），出生体重（2400 VS1890克，P <0.001），新生儿重症监护病房逗留（> 24小时，P <0.001），Apgar评分（P <0.001）更有利的OMP组中，和更少的新生儿死亡发生（3比7，P = 0.190）。
结论：OMP减少28和31周零6天，新生儿重症监护病房接诊和新生儿发病率和死亡率高风险患者之间肺结核的风险。
This translation has been produced by an automated software. If you wish to submit your own translation, please send it to translations@epistemonikos.org
Epistemonikos ID: f6c0c8a877a2769d12aaa3d170d3e7c56d676e38
First added on: May 22, 2014
Warning
This is a machine translation from an article in Epistemonikos.

Machine translations cannot be considered reliable in order to make health decisions.

See an official translation in the following languages: English

If you prefer to see the machine translation we assume you accept our terms of use